UPCA has a cure for AIDS? I'm not in this stock yet, but it's worth reading the PR.
New Technologies & Concepts, Inc. Receives Patient
Documentation From Govt. Of Spain Following
Announcement Of Major Breakthrough In Field Of
HIV Research
LAS VEGAS--(BW HealthWire)--July 19, 1999--New Technologies & Concepts, Inc. (NTC), a Research and Development
Company, announced today that as a follow-up to its announcement on June 16, 1999 of its major breakthrough in the fight
against the human immunodeficiency virus (HIV), it has received documentation from the Government of Spain verifying the
authenticity of the patients who have been treated and sent letters regarding their treatment. Their regular monthly checkups
have shown no recurrence of the virus to date. In fact, ONE HUNDRED PERCENT (100%) of the patients tested showed
COMPLETE REVERSAL of the HIV virus with VIRTUALLY NO SIDE EFFECTS!
The founder of the company, Alfred Flores, an honor graduate of the University of Madrid and the University of Colorado, has
done extensive research into the area of immunology at his own laboratory located just outside of Lisbon, in Portugal. It was
there that he developed the Plasma Plus formula, which was used to treat these patients. The letters received further verify that
the tests conducted on patients in Madrid, which showed complete reversal from the immune system of the HIV infection, still
show no reintroduction of the virus after a period of more than eighteen months.
The letters give the patient's name and address, their patient number, identification number, their original CD-4 counts at the
commencement of the treatment, and their current CD-4 counts after more than 18 months.
The patients were originally diagnosed with AIDS in 1995 at the Hospital of Madrid and Mr. Flores was then given permission
by the courts to treat them with Plasma Plus which is done, in most cases, over a 3-month period.
This documentation verifies that all of the patients have been tested monthly at the General Hospital in Madrid over the past 18
months. Their blood profiles show that prior to being administered the Plasma Plus treatment, some of the patients had CD-4
counts under 400, usually associated with AIDS, and some even as low as 200.
They are all currently in the normal 800 - 1,200 CD-4 count range and aside from taking vitamins and following a low calorie
diet, they have not taken any medication of any kind for the virus since the original Plasma Plus treatments.
Results from the findings of the Plasma Plus treatment are nothing short of ''Phenomenal,'' according to the doctors in Madrid
who oversaw the treatments.
The majority stockholder in NTC is Uniprime Capital Acceptance, Inc. (OTC BB: UPCA - news) of Las Vegas, Nevada, a
diversified holding company involved in the acquisition of retail automotive dealerships throughout the United States, along with
planned expansion into the areas of non-prime financing, industry consulting and insurance-related services.
NTC and Uniprime are currently working on additional sites around the world to demonstrate the results of Plasma Plus before
embarking on a worldwide marketing campaign.
The documentation regarding five (5) of the patients will be posted on the Uniprime web-site which is located at:
www.uniprimeinc.com .
In addition to the testimonials of the patients, three (3) of the doctors who participated in the study will be forwarding their own
WRITTEN TESTIMONIALS as to the results of the tests and this information is expected to be in the hands of Mr. Flores
and top Uniprime personnel by next week.
For further information, please contact Mr. Alfred Flores through the corporate offices of Uniprime at 1-888-892-2002 Or
1-702-798-5420.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are
not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ
materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the
company's control with respect to market acceptance of new technologies or products or delays in testing and evaluation of
products or in information supplied by others and other risks detailed from time to time in company documents furnished to
investors.
Contact:
Uniprime
Mr. Alfred Flores
888/892-2002
or
702/798-5420 |
